The Heart Failure With Preserved Ejection Fraction (HFpEF) Pathophysiology Study.
Maneno muhimu
Kikemikali
Maelezo
The study will be a pathophysiological, single-centre, observational study, in which all 4 groups, including the parallel-group will be investigated in terms of qualitative-, echocardiographic-, arterial resistance, exercise testing (CPEX and 6-MWT), endothelial dysfunction assessment by Laser Doppler and vascular biomarker measurements. We intend to investigate if there is increasing arterial resistance from group "A" to group "D" and a significant difference in arterial resistance between groups "D" and "E" by measuring the PWV.
Primary Outcome Our primary outcome will be a difference in arterial resistance between the groups and the parallel group, as measured by aortic PWV.
Secondary Outcomes
The secondary outcomes are to assess and compare endothelial function and cardiovascular performance in all groups as measured by the following:
- Blood tests: NTproBNP, Galectin-3
- Urinalysis: Albumin, Creatinine and Metabolite profiles ("metabolomics"), related to cardiovascular risk and insulin resistance
- Transthoracic echocardiography (TTE) indices of LV diastolic function, tissue Doppler imaging and strain rate imaging
- Exercise tolerance: 6-minute walk test and a Cardiopulmonary Exercise Test (CPEX)
- Microvascular function: Laser Doppler
Tarehe
| Imethibitishwa Mwisho: | 08/31/2019 |
| Iliyowasilishwa Kwanza: | 06/08/2017 |
| Uandikishaji uliokadiriwa Uliwasilishwa: | 06/12/2017 |
| Iliyotumwa Kwanza: | 06/13/2017 |
| Sasisho la Mwisho Liliwasilishwa: | 09/25/2019 |
| Sasisho la Mwisho Lilichapishwa: | 09/26/2019 |
| Tarehe halisi ya kuanza kwa masomo: | 06/05/2017 |
| Tarehe ya Kukamilisha Msingi iliyokadiriwa: | 12/30/2018 |
| Tarehe ya Kukamilisha Utafiti: | 12/30/2018 |
Hali au ugonjwa
Uingiliaji / matibabu
Other: no intervention
Awamu
Vikundi vya Arm
| Mkono | Uingiliaji / matibabu |
|---|---|
| Group A males or females aged > 70 years without major systemic comorbidities (resting blood pressure <140/90 mmHg, no history diabetes mellitus according to WHO criteria). | |
| Group B males or females aged >70 years with hypertension, defined as a documented blood pressure of Systolic Blood Pressure (SP >140 mmHg or >90mmHg Diastolic Blood Pressure) without diabetes mellitus and HF defined as: a) relevant symptoms/signs/radiographic findings as indicated by Boston criteria b) need for diuretic therapy. | |
| Group C male or female aged > 70 years with diabetes mellitus (defined according to the World Health Organization (WHO)) AND hypertension, without HF defined as: a) relevant symptoms/signs/radiographic findings as indicated by Boston criteria38 b) need for diuretic therapy. | |
| Group D male or female aged >70 years with HFPEF, defined as signs and symptoms of HF with LVEF>50% and raised natriuretic peptides (BNP>35pg/ml or NT-proBNP>125pg/ml) along with one other criteria: i) structural heart disease (left atrial enlargement or left ventricular hypertrophy) on TTE, ii) evidence of LV diastolic dysfunction based on ESC Guidelines 2016, or iii) hospitalization with heart failure within 12 months prior to study entry. | |
| Group E male or female aged >70 years with HFREF, defined as HF with LVEF <40% on TTE) |
Vigezo vya Kustahiki
| Zama zinazostahiki Kujifunza | 70 Years Kwa 70 Years |
| Jinsia Inastahiki Kujifunza | All |
| Njia ya sampuli | Non-Probability Sample |
| Hupokea Wajitolea wa Afya | Ndio |
| Vigezo | Inclusion Criteria: - Group A: males or females aged > 70 years without major systemic comorbidities (resting blood pressure <140/90 mmHg, no history diabetes mellitus according to WHO criteria). - Group B: males or females aged >70 years with hypertension, defined as a documented blood pressure of Systolic Blood Pressure (SP >140 mmHg or >90mmHg Diastolic Blood Pressure) without diabetes mellitus and HF defined as: a) relevant symptoms/signs/radiographic findings as indicated by Boston criteria b) need for diuretic therapy. - Group C: male or female aged > 70 years with diabetes mellitus (defined according to the World Health Organization (WHO)) AND hypertension, without HF defined as: a) relevant symptoms/signs/radiographic findings as indicated by Boston criteria38 b) need for diuretic therapy. - Group D: male or female aged >70 years with HFPEF, defined as signs and symptoms of HF with LVEF>50% and raised natriuretic peptides (BNP>35pg/ml or NT-proBNP>125pg/ml) along with one other criteria: i) structural heart disease (left atrial enlargement or left ventricular hypertrophy) on TTE, ii) evidence of LV diastolic dysfunction based on ESC Guidelines 2016, or iii) hospitalization with heart failure within 12 months prior to study entry. - Group E (parallel group): male or female aged >70 years with HFREF, defined as HF with LVEF <40% on TTE) Exclusion Criteria: - Acute coronary syndrome (including MI), cardiac surgery, other major CV surgery within 3 months, or urgent percutaneous coronary intervention (PCI) within 30 days of entry. - Patients who have had an MI, coronary artery bypass graft (CABG) or other event within the 6 months prior to entry unless an echo measurement performed after the event confirms a LVEF ≥50%. - Current acute decompensated HF requiring intravenous therapy - Alternative reason for shortness of breath such as: significant pulmonary disease or severe COPD, haemoglobin (Hb) <10 g/dl, or body mass index (BMI) > 40 kg/m2. - Severe left-sided valvular heart disease - Hypotension (systolic BP <100 mm Hg). - Severe Liver failure - Primary pulmonary hypertension - Bedbound/immobile patients - Chronic renal failure with creatinine of >250 μmol/l - Significant Peripheral Vascular Disease (PVD), defined as having signs of absent peripheral pulses or reported claudication pain or documented history of PVD |
Matokeo
Hatua za Matokeo ya Msingi
1. Arterial stiffness [30 minutes]
Hatua za Matokeo ya Sekondari
1. Endothelial function [15 minutes]
2. Blood test [5 minutes]
3. Blood test, marker of fibrosis [15 minutes]
4. Transthoracic echocardiography [45 minutes]
5. Exercise Tolerance [30 minutes]
6. Urinalysis [10 minutes]
